We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Enhancement of Functional Recovery After Peripheral Nerve Injury With Tacrolimus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00950391
Recruitment Status : Withdrawn (PI unable to secure funding for the project so study was not pursued.)
First Posted : July 31, 2009
Last Update Posted : February 13, 2018
Sponsor:
Information provided by (Responsible Party):
Washington University School of Medicine

Brief Summary:

Tacrolimus (FK506) is an immunosuppressive medication that promotes organ allograft survival. It has also been shown to enhance nerve regeneration and muscle reinnervation in animals but these properties have not previously been studied in patients. Moreover, currently there is no method in clinical use to speed the rate of recovery after nerve injury. The objective of this study is to explore the ability of tacrolimus to benefit the treatment of patients with peripheral nerve injury. To minimize the morbidity of tacrolimus therapy, its phase-specific effects on nerve regeneration and muscle reinnervation will be defined in the murine model to permit further limitation of the duration of therapy. The investigators hypothesize that treatment with tacrolimus after autogenous peripheral nerve reconstruction will accelerate nerve regeneration, reduce the period of denervation and improve muscle reinnervation and recovery in patients with peripheral nerve injury.

There are 2 specific aims:

  1. Determine the safety and efficacy of tacrolimus following reconstructive nerve surgery in a double-blind placebo-controlled randomized pilot clinical trial of patients with severe nerve injuries of the extremities;
  2. Correlate the quality of life outcome with assessment of functional recovery after surgical reconstruction of patients with severe peripheral nerve injuries of the extremities.

Condition or disease Intervention/treatment Phase
Peripheral Nerve Injury Drug: Tacrolimus Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Enhancement of Functional Recovery After Peripheral Nerve Injury With Tacrolimus
Study Start Date : August 2010
Estimated Primary Completion Date : September 2014
Estimated Study Completion Date : September 2015

Resource links provided by the National Library of Medicine

Drug Information available for: Tacrolimus
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Tacrolimus
Treatment with tacrolimus following nerve repair/reconstruction
Drug: Tacrolimus
Tacrolimus 3 mg/day taken twice daily to maintain blood level of 3-6 ng/ml for duration of 1 year or less
Other Name: FK506, Prograf



Primary Outcome Measures :
  1. Functional Recovery [ Time Frame: 1-1.5 years ]
  2. Incidence of adverse events. [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Recovery time. [ Time Frame: 1.5 years ]
  2. Recovery of sensation. [ Time Frame: 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. have deficit of upper extremity function of MRC grade 0-2
  2. are candidates for surgical reconstruction
  3. are no more than 10 months after their injury
  4. have no ongoing infectious or wound healing complications related to injury or previous surgery or otherwise
  5. have no history of cancer or have been treated and free of cancer for at least 5 years
  6. age 18-50
  7. agree to participate in the study

Exclusion Criteria:

  1. positive HIV or hepatitis blood test
  2. recent history of cancer within the past 5 years
  3. history of severe and recurrent infections (such as hidradenitis suppurativa)
  4. presence of ongoing and unresolved infectious concerns related to original injury or previous surgery (such as osteomyelitis, wound infection) or otherwise
  5. presence of ongoing wound healing problems related to the injury or previous surgery or otherwise
  6. presence of moderate or severe liver disease as indicated by aspartate transaminase (AST), alanine transaminase (ALT), amino alkaline phosphatase, or total bilirubin levels greater than the upper limit of normal (ULN)
  7. creatinine level ≥ 1.0 mg/dl or more than ULN
  8. hemoglobin value of <9.0 mg/dl, a white blood cell count <3,000 cells/mm3, or platelet count <100,000 platelets/mm3
  9. uncontrolled hypertension with systolic blood pressure >160 mm Hg and diastolic blood pressure >90 mm Hg at screening and baseline
  10. hyperkalemia (serum K > ULN)
  11. pancreatitis or diabetes mellitus (fasting blood sugar ≥ 110 mg/dl or postprandial blood sugar ≥ 160 mg/dl) or a history of these
  12. heart disease or abnormal electrocardiogram (ECG) especially arrhythmia and change in ST/T or a previous history of these
  13. history of serious drug hypersensitivity
  14. age less than 18 or greater than 50
  15. incarceration prior to or at the time of consideration for enrollment (any participant who becomes incarcerated during the course of the study will be excluded)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00950391


Sponsors and Collaborators
Washington University School of Medicine
Investigators
Principal Investigator: Thomas H Tung, MD Washington University School of Medicine

Responsible Party: Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT00950391     History of Changes
Other Study ID Numbers: FK50600
First Posted: July 31, 2009    Key Record Dates
Last Update Posted: February 13, 2018
Last Verified: February 2018

Keywords provided by Washington University School of Medicine:
peripheral nerve injury
peripheral nerve surgery
nerve repair
nerve graft

Additional relevant MeSH terms:
Wounds and Injuries
Peripheral Nerve Injuries
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Trauma, Nervous System
Tacrolimus
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action